{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056885","form_type":"8-K","ticker":"ORGO","cik":"0001661181","company_name":"Organogenesis Holdings Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.476783+00:00","generated_at":"2026-06-02T06:19:22.949738+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Organogenesis beats Q1 revenue guidance with $110.0M; net loss narrows to $2.1M","bullets":["Net revenue $110.0M, up 2% YoY, exceeding high-end of FY2024 guidance.","Advanced Wound Care revenue $103.9M (+3%); Surgical & Sports Medicine $6.1M (-9%).","GAAP net loss $2.1M ($0.02 EPS); adjusted net loss $1.4M; Adjusted EBITDA $2.6M.","FY2024 guidance reaffirmed: revenue $445M-$470M; adjusted EBITDA $15.8M-$35M.","Cash $89.3M, debt $64.9M as of March 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056885","json":"https://secwatch.observer/filing/0000950170-24-056885.json","markdown":"https://secwatch.observer/filing/0000950170-24-056885.md","text":"https://secwatch.observer/filing/0000950170-24-056885.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661181/000095017024056885/0000950170-24-056885-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661181/000095017024056885/orgo-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:19:22.949738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3520fbc7a47607bf06afba3bb66000f9a7b274f3","claim":"Organogenesis Holdings Inc. reported first quarter ended March 31, 2024 results: revenue $110.0 million, net income $2.1 million, EPS $(0.02) per share. Guidance reaffirmed.","evidence_excerpt":"Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31st, 2024. First Quarter 2024 Financial Results Summary: • Net revenue of $110.0 million for the first quarter of 2024, an increase of $2.3 million compared to net revenue of $107.6 million for the first quarter of 2023. Net revenue for the first quarter of 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661181/000095017024056885/0000950170-24-056885-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$110.0 million"},{"label":"Net income","value":"$2.1 million"},{"label":"EPS","value":"$(0.02) per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}